Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FORMA, BI in R&D Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

FORMA, BI in R&D Alliance

Will focus on developing novel cancer drugs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim and FORMA Therapeutics have entered into a R&D collaboration to discover and develop novel drug candidates for the treatment of cancer. The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.

FORMA will receive a total of $65 million in upfront payments and research funding to screen for and optimize compounds against multiple oncology targets during the next four years. FORMA is eligible to receive as much as $750 million in milestones for programs resulting from the collaboration.

“Many of the ‘un-druggable’ and/or novel targets in oncology involve protein-protein interactions,” said Kenneth Bair, Ph.D., senior vice president and head of R&D of FORMA. “We are really excited about tackling these essential targets with Boehringer Ingelheim.”

“This creative deal provides Boehringer Ingelheim with access to our drug discovery capabilities in cancer but also offers FORMA and our shareholders several opportunities to realize early return through assets developed under this collaboration,” said Steven Tregay, Ph.D., chief executive officer of FORMA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics